{"entity":{"id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","aka":[],"tldr":"A phase 1/2 trial of JS111 capsules (AP-L1898) in non-small-cell lung cancer, run by Suzhou Junjing BioSciences Co., Ltd., active and no longer recruiting.","summary":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations is a phase 1/2 interventional study registered as NCT06940401 by Suzhou Junjing BioSciences Co., Ltd., with 44 participants enrolled, started 2025-04-30 and due to reach its primary completion in 2028-07-30. Interventions recorded: JS111 capsules (AP-L1898).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06940401","url":"https://clinicaltrials.gov/study/NCT06940401"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06940401","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate JS111 Capsules in Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations.","sponsor":"Suzhou Junjing BioSciences Co., Ltd.","enrolled":44,"outcomes":[]},"route":"/trials/nct06940401/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}